A Phase I, Double-blind, Randomized, Placebo-controlled, Single-dose, Dose-escalation Study of KRN23 in X-linked Hypophosphatemia

Trial Profile

A Phase I, Double-blind, Randomized, Placebo-controlled, Single-dose, Dose-escalation Study of KRN23 in X-linked Hypophosphatemia

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2014

At a glance

  • Drugs Burosumab (Primary) ; Burosumab (Primary)
  • Indications Hyperphosphataemia
  • Focus Adverse reactions
  • Sponsors Kyowa Hakko Kirin
  • Most Recent Events

    • 11 Oct 2013 New trial record
    • 08 Oct 2013 Results presented at the 35th Annual Meeting of the American Society for Bone and Mineral Research.
    • 07 Oct 2013 Results published in a Kyowa Hakko Kirin media release and presented at the American Society of Bone Mineralization Research (ASBMR) 2013 Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top